Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis.
about
Aspergillus infections in transplant recipients.Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosisActivity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.Carrier effects on biological activity of amphotericin B.Antifungal prophylaxis during neutropenia and immunodeficiencyNew and emerging antifungal agents: impact on respiratory infections.Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.Inhaled therapeutics for prevention and treatment of pneumoniaSafety of aerosolized amphotericin B.Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation.Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature.The utility of a nebulised intra-tracheal rat model of invasive pulmonary aspergillosis.Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis.Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis.Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.Pharmacokinetics of aerosol amphotericin B in rats.Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis.Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patientsAerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice.Use of immunoblotting to detect Aspergillus fumigatus antigen in sera and urines of rats with experimental invasive aspergillosis.Model of recurrent pulmonary aspergillosis in rats.Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis.The serum glucan level and pathological changes of antifungal treatment for lower respiratory tract infection of Candida albicans.Disseminated aspergillosis due to Aspergillus flavus in an experimental model: efficacy of azole therapy.Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.Inactivity of terbinafine in a rat model of pulmonary aspergillosis.Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis.
P2860
Q33719294-EE45CDB9-9932-4E22-B2A7-E58E6852FA26Q33749615-7A02CD9E-46C6-46D8-A758-9228895694B4Q33883785-8AF618AB-F5C2-4370-8629-B4A2DF9E1271Q35134300-FCF5F0A1-5792-4876-BAAE-D49622A21855Q35372581-30393FD6-673F-43A7-8766-7E51F7D52D2DQ35374928-16430690-FF86-48E3-AF9F-A740835850F6Q35627629-E9F87E59-9F7D-4AD8-B6F0-540068C890D1Q35904922-6D58123C-B29D-491F-86A9-7F6C3C269567Q35925366-B177C0CE-0AC6-4A7B-90DB-23E8CF4EF2B6Q36945011-07A76744-1E5A-44CA-8A6D-E0CE0908B181Q37216741-4862FCBF-E1CA-4225-8580-D01F1F1671D9Q38211509-7179DBB8-0072-4A8C-B76C-9143E13D4A99Q38938053-01D3240C-604B-42A4-84D0-7ACFF8660031Q39027209-01AE124C-2F49-4BA9-91CF-4E025414FE5DQ39780220-B70B393D-8610-4266-80D1-F6F31FC56F56Q39783583-CB6A34B0-5E87-439C-88F6-AD9AB100A03CQ39815159-1FB243AF-8C6E-434E-8CC2-09C7606FECF6Q39866214-9A55676F-F987-4EB5-8688-6C64F4B16630Q39866778-608B7E44-6783-4309-A9C3-ECA349C7D718Q39879675-1845B23D-D9B9-4EB9-B51D-CAF992B413EBQ40201973-33EE1DFD-1A8F-4EE6-AA37-C5D28E0566B7Q40212850-FD1B67A6-590D-4390-A811-C17AEE702132Q40695013-C02253A4-D809-467A-A3AD-844111479FCDQ41570426-B82119F1-33E6-4B5B-BB9F-9116672A396AQ44474657-B60B8711-F04D-4682-BCB8-8BEE0301A94EQ46639396-A6A3A10D-0409-48D0-8AAF-D06B9791CA23Q46690197-8901596C-4110-46EE-81DF-2CEBFC2024D7Q46808821-A35A039C-0D97-46D2-BA39-AC1B16F60B42Q53626853-01FA271B-5157-4363-9A5B-C5F1D05452C9Q53709751-F505B3C1-1F64-4679-BA4B-5FC8F68D9F0F
P2860
Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Aerosol amphotericin B is effe ...... el of pulmonary aspergillosis.
@en
Aerosol amphotericin B is effe ...... el of pulmonary aspergillosis.
@nl
type
label
Aerosol amphotericin B is effe ...... el of pulmonary aspergillosis.
@en
Aerosol amphotericin B is effe ...... el of pulmonary aspergillosis.
@nl
prefLabel
Aerosol amphotericin B is effe ...... el of pulmonary aspergillosis.
@en
Aerosol amphotericin B is effe ...... el of pulmonary aspergillosis.
@nl
P2093
P2860
P356
P1476
Aerosol amphotericin B is effe ...... el of pulmonary aspergillosis.
@en
P2093
Armstrong D
Bernard EM
Schmitt HJ
P2860
P304
P356
10.1128/AAC.32.11.1676
P407
P577
1988-11-01T00:00:00Z